Historical Valuation
Vaxcyte Inc (PCVX) is now in the Fair zone, suggesting that its current forward PS ratio of 162.18 is considered Fairly compared with the five-year average of -11.91. The fair price of Vaxcyte Inc (PCVX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：46.05
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vaxcyte Inc (PCVX) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 3.35 , the current P/B ratio is approximately -37.65% higher. Relative to its 5-year average P/B ratio of 3.68, the current P/B ratio is about -43.25% higher. Vaxcyte Inc (PCVX) has a Forward Free Cash Flow (FCF) yield of approximately -10.21%. Compared to its 3-year average FCF yield of -7.18%, the current FCF yield is approximately 42.05% lower. Relative to its 5-year average FCF yield of -7.30% , the current FCF yield is about 39.78% lower.
P/B
Median3y
3.35
Median5y
3.68
FCF Yield
Median3y
-7.18
Median5y
-7.30
Competitors Valuation Multiple
AI Analysis for PCVX
The average P/S ratio for PCVX competitors is 234.74, providing a benchmark for relative valuation. Vaxcyte Inc Corp (PCVX.O) exhibits a P/S ratio of 162.18, which is -30.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PCVX
1Y
3Y
5Y
Market capitalization of PCVX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PCVX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PCVX currently overvalued or undervalued?
Vaxcyte Inc (PCVX) is now in the Fair zone, suggesting that its current forward PS ratio of 162.18 is considered Fairly compared with the five-year average of -11.91. The fair price of Vaxcyte Inc (PCVX) is between to according to relative valuation methord.
What is Vaxcyte Inc (PCVX) fair value?
PCVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vaxcyte Inc (PCVX) is between to according to relative valuation methord.
How does PCVX's valuation metrics compare to the industry average?
The average P/S ratio for PCVX's competitors is 234.74, providing a benchmark for relative valuation. Vaxcyte Inc Corp (PCVX) exhibits a P/S ratio of 162.18, which is -30.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Vaxcyte Inc (PCVX) as of Jan 10 2026?
As of Jan 10 2026, Vaxcyte Inc (PCVX) has a P/B ratio of 2.09. This indicates that the market values PCVX at 2.09 times its book value.
What is the current FCF Yield for Vaxcyte Inc (PCVX) as of Jan 10 2026?
As of Jan 10 2026, Vaxcyte Inc (PCVX) has a FCF Yield of -10.21%. This means that for every dollar of Vaxcyte Inc’s market capitalization, the company generates -10.21 cents in free cash flow.
What is the current Forward P/E ratio for Vaxcyte Inc (PCVX) as of Jan 10 2026?
As of Jan 10 2026, Vaxcyte Inc (PCVX) has a Forward P/E ratio of -7.31. This means the market is willing to pay $-7.31 for every dollar of Vaxcyte Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vaxcyte Inc (PCVX) as of Jan 10 2026?
As of Jan 10 2026, Vaxcyte Inc (PCVX) has a Forward P/S ratio of 162.18. This means the market is valuing PCVX at $162.18 for every dollar of expected revenue over the next 12 months.